Three cohorts up the ladder, no dose-limiting toxicity reported, and the top rung is the one carried into expansion
A dose-escalation study exists to find the dose where harm starts.
Elicera ran all three cohorts and did not report finding it.
Elicera Therapeutics' safety board has recommended the highest dose of the CAR T-cell therapy ELC-301 for the Phase IIa part of the CARMA study. No dose limiting toxicities were reported in the completed Phase I. Phase IIa dosing waits on approval from the Swedish Medical Products Agency.
What the safety board decided
Elicera Therapeutics is a clinical-stage cell and gene therapy company based in Uppsala, Sweden. It announced on September 9 that its Data Safety and Monitoring Board has completed the final assessment of CARMA's Phase I part. The board recommended the highest dose for continuation of the study into Phase IIa.
CARMA tests the CAR T-cell therapy ELC-301 in B-cell lymphoma. It is built in two parts. The dose-escalation part, Phase I, enrolled 12 patients and is now complete; the dose-expansion part, Phase IIa, will enrol 6.
The study is run in collaboration with Uppsala University as co-sponsor, at Uppsala University Hospital and Karolinska University Hospital in Huddinge.
Twelve patients through the escalation. No dose limiting toxicities reported.
CARMA at a glance
- Asset: ELC-301, a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with Elicera's iTANK platform.
- Indication: B-cell lymphoma.
- Phase I: dose escalation, 12 patients, planned as three cohorts of three, three and six. Complete.
- Phase IIa: dose expansion, 6 patients, at the maximum tolerated dose.
- Sites: Uppsala University Hospital and Karolinska University Hospital in Huddinge. Co-sponsor: Uppsala University.
Why the highest dose and the maximum tolerated dose are not the same sentence here
The Phase I design has a specific shape. Three cohorts were planned, with three patients in the first and second and six in the third, and the third cohort was expected to receive the maximum tolerated dose.
That design assumes toxicity will eventually set the ceiling. In CARMA, on what has been reported, it did not.
So the dose the board recommended is the highest dose the protocol went to. On the reported data it is not a dose that toxicity picked out, and the two are worth keeping apart when reading the announcement.
If you have written a dose justification for a protocol like this one, regulatory affairs experts get matched to paid consulting work through GTC's Expert Network: join free.
What the efficacy data has shown so far
The latest CARMA data, press released on August 11, covered eleven evaluated patients. All had achieved disease control, meaning no disease progression, one month after treatment. 91 percent, 10 of 11, had obtained an objective tumour response.
Six of the eleven evaluated patients, 55 percent, reached a complete metabolic response, which Elicera describes as disease-free status. Of those six, four remained disease-free, one for at least 18 months and one for at least 12 months.
10 of 11 evaluated patients had an objective tumour response. Six were disease-free.
One number is still open. Elicera says it will update preliminary efficacy data from all 12 Phase I patients once the final one completes the one-month evaluation. The figures above are not the final Phase I read.
What ELC-301 and iTANK actually are
ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen.
The iTANK platform adds a transgene encoding a neutrophil activating bacterial protein, or NAP. Elicera's stated aim is that NAP secreted from the CAR T-cells enhances their function and activates a parallel bystander response through CD8+ killer T cells.
That matters for how the safety read should be taken. The engineered product is doing two things at once, so a clean toxicity record in twelve patients speaks to this construct at these doses. It is not a statement about arming platforms generally.
What stands between the recommendation and a dosed patient
Once approval from the Swedish Medical Products Agency has been received, Phase IIa patients will be treated at the highest dose level. The board's recommendation is an input to that decision, not a replacement for it.
No date is given for the regulator's response. Anyone building a timeline off this announcement is building it off a step that has not happened yet.
Elicera's CEO Johan Liwing framed the recommendation as a confidence signal rather than a result: "Built on the accumulated efficacy signals we have seen so far in Phase I, the DSMB's positive recommendation strengthens our confidence in ELC-301." He added that the company can now proceed with Phase IIa as soon as possible after MPA approval.
What this means for a CGT program
GTC analysis: the first consequence is regulatory. When no dose-limiting toxicity is observed, the expansion dose is bounded by the protocol rather than by the patients. ELC-301 carries two active mechanisms at once, the CAR itself and the iTANK-driven NAP secretion, so that split matters more here than in a single-mechanism CAR-T.
The dose justification has to rest on the escalation design and the exposure data for both mechanisms together, not on an observed maximum tolerated dose. A written rationale along these lines is standard practice ahead of MPA review, not a novel step. What is not yet public is whether Elicera's version does that, since there is no MTD to point to instead.
GTC analysis: the second consequence is CMC. Expanding at the top of the tested range means every patient needs a product that hits the highest specification. There is no lower cohort to fall back on if a batch comes in under it.
For a six-patient expansion that is a real constraint on release testing and on batch scheduling. A single out-of-specification batch is a meaningful fraction of the cohort.
GTC analysis: the third consequence is timeline. Elicera's own wording puts the regulator, not the board, on the critical path. A milestone dated from the recommendation is dated from the wrong event.
A comparison point would help here, and there is not an honest one to offer. Elicera has not published the dose levels, the MPA response time, or the final Phase I efficacy set. There is nothing to benchmark this against without inventing the numbers.
Frequently asked questions
What did Elicera's safety board recommend?
The Data Safety and Monitoring Board completed its final assessment of the ongoing Phase I part of the CARMA study. That study tests the CAR T-cell therapy ELC-301 in B-cell lymphoma. The board recommended the highest dose for continuation of the study into Phase IIa. Elicera Therapeutics announced the recommendation on September 9, 2026, after the board reviewed the Phase I safety data.
What is ELC-301, and what is the CARMA study?
ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with Elicera's iTANK platform. CARMA is a Phase I/IIa study of its safety and efficacy in patients with B-cell lymphoma. Uppsala University is the co-sponsor, and the study runs at Uppsala University Hospital and Karolinska University Hospital in Huddinge. It has two parts: a dose-escalation Phase I in 12 patients, now complete, and a dose-expansion Phase IIa in 6 patients.
Were there any dose-limiting toxicities in Phase I?
No dose limiting toxicities have been reported in Phase I, according to Elicera's announcement. Phase I was planned as three cohorts: three patients in the first and second, and six in the third. The third cohort was expected to receive the maximum tolerated dose. Because no dose-limiting toxicity was reported, the dose the safety board recommended for Phase IIa is the highest dose level the study tested.
What efficacy data has Elicera reported so far?
The latest CARMA data, press released on August 11, 2026, covered eleven evaluated patients. All had achieved disease control, meaning no disease progression, one month after treatment, and 91 percent, or 10 of 11, had obtained an objective tumour response. Six patients, 55 percent, had a complete metabolic response, described as disease-free status. Of those, four remained disease-free, one for at least 18 months and one for at least 12 months. Elicera says it will update preliminary efficacy data from all 12 Phase I patients once the final Phase I patient has undergone the one-month evaluation.
What has to happen before Phase IIa patients are dosed?
Approval from the Swedish Medical Products Agency, the MPA. Elicera states that once MPA approval has been received, Phase IIa patients will be treated at the highest dose level. The safety board's recommendation is an input to that step, not a substitute for it, and the announcement gives no date for the regulator's response.
Sources
- Elicera Therapeutics Receives Safety Committee Recommendation to Use Highest ELC-301 Dose as CARMA Moves Toward Phase IIa in B-cell Lymphoma – Elicera Therapeutics AB (publ), press release via Cision, Uppsala, September 9, 2026, 08:45 CET. Every factual claim in this article traces to this release, including the study design, the patient numbers, the August 11 efficacy figures, the MPA approval step, the ELC-301 and iTANK descriptions, and the quote from CEO Johan Liwing. The August 11, 2026 efficacy figures are given here as Elicera reported them in this release.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients — join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy — for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.